PrioThera Series B Investment
Tuesday, 03 February 2026
Byrne Wallace Shields LLP is pleased to have acted for our client, biotech company, PrioThera in relation to its €36 million Series B fundraising to advance the development of mocravimod, a drug taken orally that activates cell receptors to trigger part of the body’s immune response against myeloid leukaemia.
This financing round was led by Multi Invest VCC (Singapore), Finance 1805 SA (Geneva Switzerland), PrioThera 4See Ventures Partnership (Geneva, Switzerland), Olexco SA (Geneva, Switzerland), and Cantrak (Ixelles, Belgium) as well as existing investors Fountain Healthcare Partners (Dublin, Ireland) and HealthCap (Lausanne, Switzerland), Earlybird Venture Capital (Germany), and Evren Üçok.
The Byrne Wallace Shields LLP Team who advised on this transaction included Catherine Dowling (Partner, Corporate & Life Sciences), Elizabeth Ryan (Partner, Banking & Finance), Zelda Deasy (Corporate & Data Protection), Catherine Cusack (Managing Associate, Corporate & Life Sciences) and Alban O’Callaghan (Managing Associate, Corporate).
